UCLA Patient Newsletter Issue 50:
Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment
We are happy to announce that the investigator initiated trial Pembro IST is anticipated to expand enrollment to UCLA satellite sites. Pembrolizumab is an antibody that inhibits the PD-1/PD-L1 immune checkpoint and allows the immune system to destroy cancer cells. Pembro IST is a study of pembrolizumab in patients with non-small cell lung cancer whose tumors tested positive for the protein PD-L1 (≥1%) using an approved test and have an EGFR mutation. To be eligible, patients must also be tyrosine kinase inhibitor (TKI) treatment naïve. Patients will receive pembrolizumab (200mg) every 3 weeks by infusion. After disease progression on pembrolizumab, patients will be followed through periodic follow-up for evaluation of duration of response with an EGFR TKI as well as survival. Interested patients must provide tissue for PD-L1 biomarker analysis prior to the start of treatment. The trial is open to enrollment at UCLA Main Campus and UCLA satellite sites including Irvine, Alhambra, and Laguna Hills and is anticipated to open at additional satellite sites including Torrance, Porter Ranch, and others.
Annals of Oncology Publication
An article discussing the long-term survival and clinical activity of pembrolizumab as firstline treatment for patients with PD-L1 positive advanced non-small cell lung cancer (NSCLC) was recently published in Annals of Oncology. The results were based on the open-label phase 1b KEYNOTE-001 trial in which 101 treatment-naïve patients with advanced NSCLC whose tumors were positive for PD-L1 expression were randomized to receive pembrolizumab 2 or 10 mg/kg every 3 or 2 weeks. Investigators found that the overall response rate was 27% and the median overall survival was 22.1 months. The greatest efficacy was observed in patients whose tumors had a high expression of PD-L1 (≥ 50%) with objective response rate (ORR), 12-month progression free survival (PFS), and 12-month overall survival (OS) of 51.9%, 54%, and 85%, respectively. The ORR, 12-month PFS, and 12-month OS for the overall population were 26.7%, 35%, and 71%, respectively. Pembrolizumab and other PD-(L)1 inhibitors continued to be investigated in studies conducted at UCLA and in the TRIO-US Network.
TOTR at IASLC 17th Annual Targeted Therapies of Lung Cancer
The 17th Annual Targeted Therapies of Lung Cancer Meeting was held in Santa Monica from February 22nd through February 25th. The meeting featured talked from many of the TRIO-US physicians, and collaborators from throughout the country. Talks were given by Dr. Garon on ramicirumab combinations and OX-40 agonist antibodies as single agents and in combination with PD-1 or PD-L1 inhibitors. Dr. Goldman presented on ALK inhibitors in combination with immunotherapy as well as abemaciclib, an oral CDK4/6 inhibitor, that is being investigated in the JPBJ trial and was studied in TRIO-US as part of the Juniper trial. The conference also featured a poster presentation given by nurse practitioner, Melody Mendenhall titled, “Combination rociletinib and atezolizumab therapy for NSCLC: Review of three patients” as well as a poster presentation by Dr. Lisberg titled, “A phase II study of pembrolizumab in EGFR mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced non-small cell lung cancer (NSCLC).” We look forward to these continued collaborations, and to the discoveries leading to the advancement of cancer therapeutics.